Physician profile
B Alan Bottenberg
NPI 1942210349
$11,360.63
in general payments reported to CMS, 2019-2025
48 companies · $1,808 in 2025
The $1,808 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,611 · 2020: $2,104 · 2021: $1,449 · 2022: $1,261 · 2023: $878 · 2024: $1,250 · 2025: $1,808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,924 · Education: $12.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,924.01 |
| Education | $12.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,547.17 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,400.77 | 2019-2025 | Ubrelvy, Synthroid |
| Amgen INC. | $1,212.20 | 2019-2025 | Repatha, Repatha |
| Novo Nordisk INC | $879.02 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $739.30 | 2019-2025 | |
| Amarin Pharma, INC. | $643.25 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $512.47 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $480.24 | 2021-2025 | |
| Lilly USA, LLC | $390.40 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $363.58 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Astellas Pharma US INC | $297.99 | 2019-2024 | Veozah, Myrbetriq |
| Regeneron Healthcare Solutions, INC. | $219.32 | 2019 | |
| Esperion Therapeutics, INC. | $209.07 | 2021-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $200.88 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $198.15 | 2019-2023 | Livalo |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw B Bottenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.